Motolimod combined with cetuximab (anti-EGFR antibody), or conventional chemotherapy, can decrease the number of Tregs in the tumor microenvironment and increase in the number of circulating EGFR-specific CD8+ T cells. Here, EGFR is linked to neoplasm.